Vaccine deliveries to Africa

Vaccines arriving at international airports is only the first step in the race for vaccine access equity

COMMENT | By Dr. Solomon Zewdu | On February 24, 600,000 doses of COVID-19 vaccine arrived in Accra, Ghana. Two days later, another 504,000 doses arrived in Abidjan, Côte d’Ivoire. These were the first international deliveries of COVID-19 vaccine through the COVAX Facility, and—with the first doses administered in both countries just days later—the first steps in what will be the largest immunisation campaign in world history. Hopefully, these milestones represent a turning point in the world’s response to the pandemic.

A wide-ranging coalition of international public health organisations and other partners, COVAX aims to ensure that every nation, regardless of resources, gets the vaccines needed to protect its people from this devastating virus. A large part of the developing world, including most of Africa, has too often been forced to wait for lifesaving innovations and treatments. Because of this chronic lack of equitable access, disease and poverty linger. COVAX was created at the start of the pandemic to mitigate these inequities. It plans to deliver 2 billion vaccine doses all over the world in 2021, including 1.3 billion to low- and middle-income countries.

This ambitious international campaign is especially crucial given the deep disparities that have marked COVID-19 vaccine distribution so far. Until very recently, the world’s richest nations had received almost all of the vaccine supply. As a result, even as some high-income nations have already immunised more than 20% of their population with at least one dose, only a few African countries have reached even 1 in 1,000 people. It is frankly impossible to defeat the virus if these disparities persist. If everyone doesn’t have the chance to get immunised, the world economy could lose as much as US$9.2 trillion and twice as many people could perish needlessly.

Nonetheless, these first introductions in Accra and Abidjan coming less than three months after COVID-19 vaccines were first introduced in high-income nations represents proof that pooling resources can help shorten the time it takes to get vaccines to lower-income countries after they are developed. Before Gavi, the Vaccine Alliance, launched the Pneumococcal Advance Market Commitment in 2009, for example, it could take up to 15 years for life-saving vaccines to reach lower-income countries. Through donor commitments, this innovative funding mechanism has dramatically increased the speed with which vaccines reached lower-income countries and has helped 60 lower-income countries introduce pneumonia vaccines at more affordable prices.

Collaborations like COVAX and its Advance Market Commitment build on these successes and are similarly helping to narrow the gap in access to COVID-19 vaccines. To keep closing this deadly gap, however, additional resources from governments, donors, and the private sector will be needed. The commitment by G7 nations in mid-February to double COVAX funding is an excellent start, but more will be required to immunise everyone.

With that in mind, we must recognise that vaccines arriving at international airports—while an important and laudable logistical feat—is only the first step. The job will not be done until these vaccines get into people’s arms. Even some of the world’s wealthiest nations, with access to substantially more doses and with expensive health systems, have struggled with their vaccination campaigns, and the job could be exponentially harder in countries with far fewer doses and public health resources. That is why governments and public health organisations across Africa are working overtime to make sure their health care systems and workers are ready to get these vaccines moving.

Many African countries have expertise in conducting rapid and effective mass vaccination campaigns, often immunising millions of people in a single week. In 2016, for example, 41,000 health workers and volunteers were recruited and trained to administer yellow fever vaccines to 14 million people in Angola and the Democratic Republic of the Congo (DRC) in just 10 days. The following year, Nigeria—despite political conflict—was able to immunise 4.7 million children against measles in only two weeks. And even amid the pandemic, Ethiopia was able to vaccinate 13 million children against measles and nearly 2 million people against cholera, thus averting the catastrophic consequences of missed vaccination campaigns.

These countries and many others in Africa already know firsthand what a successful mass vaccination campaign takes and have invested in many of the essential components, including detailed planning, real-time communication, building health worker capacity, and, critically, developing public trust in vaccines. Some nations, such as the DRC, even have experience with the ultracold temperatures needed for some COVID-19 vaccines, due to their efforts to inoculate more than 300,000 people against Ebola.

These experiences offer key lessons for vaccine delivery that the rest of the world can benefit from and will assuredly be helpful as African nations work to immunise their citizens against COVID-19. It will take enormous effort, resources, and dedication from everyone—both in Africa and around the world—to scale up vaccine delivery to the levels that are needed. Getting vaccines to Accra, Abidjan, and cities all over the planet is a vital first step in defeating this pandemic. Now the real test of whether we can achieve vaccine equity begins.

******

Dr. Solomon Zewdu is the Bill & Melinda Gates Foundation’s deputy director for health in Africa and its Africa COVID-19 response coordinator.

RELATED STORY

SPECIAL FEATURE

Why vaccine side effects might be more common in people who’ve already had COVID-19

via @LindaGeddes & @Gavi https://t.co/6SbS9hGeqC

— The Independent (@UGIndependent) February 27, 2021